Major Histocompatibility Complex Class I (MHC I)
The Major Histocompatibility Complex (MHC) is an essential genetic region in all vertebrates, known in humans as the Human Leukocyte Antigen (HLA) system, located on chromosome 6. Its primary role is to encode cell- surface proteins critical for the adaptive immune system’s ability to distinguish between “self” and “non-self.” These MHC proteins bind small peptide fragments derived from cellular proteins and display them on the cell surface for examination by T lymphocytes, thereby initiating an immune response against foreign pathogens or abnormal cells.
MHC Class I molecules are one of the two primary classes and are found on the surface of virtually all nucleated cells in the body, as well as platelets, with exceptions noted in cells of the retina and brain, and non-nucleated red blood cells. Their central task is to monitor the intracellular environment of the cell and present a snapshot of its internal protein content to Cytotoxic T Lymphocytes (CTLs), which are also known as CD8+ T cells. This function makes MHC Class I indispensable for detecting and eliminating cells infected by intracellular pathogens, particularly viruses, and abnormal cells like those that are cancerous.
Structure of the MHC Class I Molecule
The MHC Class I molecule is a heterodimer composed of two non-covalently linked polypeptide chains: a highly polymorphic, heavy alpha (α) chain and a smaller, invariant light chain called beta-2 microglobulin (β₂m). The gene for the α-chain is encoded within the HLA complex (specifically HLA-A, -B, and -C loci) on chromosome 6, while the gene for β₂m is located on chromosome 15.
The heavy α-chain is a transmembrane glycoprotein, typically around 45 kilodaltons (kDa), and consists of three external globular domains: α1, α2, and α3. It also includes a transmembrane domain that anchors the molecule to the cell membrane and a short cytoplasmic tail. The non-polymorphic β₂m molecule (12 kDa) non-covalently associates with the α3 domain and is crucial for stabilizing the overall structure and enabling a fully folded, functional conformation of the α-chain.
The peptide-binding site, or groove, is formed by the interaction of the α1 and α2 domains at the top of the molecule. This cleft is deep and narrow, structured by two α-helices forming the sides and a platform of eight antiparallel β-strands forming the floor. A key structural feature of the MHC I groove is that it is closed at both ends by conserved tyrosine residues. This characteristic restricts the size of the peptide fragments it can accommodate, typically to a length of 8 to 10 amino acids, ensuring a snug, precise fit.
Mechanism of Antigen Processing and Presentation
MHC Class I molecules present endogenous antigens—peptides derived from proteins synthesized within the cytosol of the cell. This process is often called the cytosolic or endogenous pathway and involves several intricate steps and components:
The process begins with the degradation of intracellular proteins. These can be normal “self” proteins undergoing routine turnover, defective ribosomal products (DRiPs), or, crucially, proteins associated with intracellular pathogens, such as viral proteins. These proteins are tagged with ubiquitin and fed into the proteasome, a multi-catalytic protein complex that degrades them into short peptides. These peptides are then trimmed by cytosolic proteases, resulting in fragments that are predominantly the optimal 8–10 amino acid length for MHC I binding.
Next, these antigenic peptides must be transported from the cytosol into the lumen of the endoplasmic reticulum (ER). This is accomplished by the Transporter Associated with Antigen Processing (TAP), a heterodimeric protein complex that belongs to the ABC transporter family. TAP binds the peptides on the cytoplasmic side and translocates them into the ER lumen in an ATP-dependent manner.
Simultaneously, the newly synthesized MHC Class I α-chain is folding and assembling with β₂m inside the ER. The partially folded MHC I heterodimer becomes part of a quality-control assembly known as the Peptide-Loading Complex (PLC). Key components of the PLC include the chaperone protein calreticulin, the oxidoreductase ERp57, and, most importantly, tapasin. Tapasin physically links the MHC I molecule to the TAP transporter, facilitating the transfer of peptides entering the ER and accelerating the binding and exchange of peptides to the MHC I groove. This ensures that only high-affinity peptides are loaded. Once a stable, high-affinity peptide-MHC I complex is formed, it dissociates from the PLC, exits the ER, travels through the Golgi apparatus, and is ultimately transported via a secretory vesicle to the cell surface, ready for presentation.
Functions in Immune Surveillance and Clinical Significance
The primary function of the MHC Class I-peptide complex at the cell surface is to serve as a signaling beacon to the immune system. It mediates cellular immunity by presenting its bound peptide to the T-cell Receptor (TCR) of a circulating CD8+ Cytotoxic T Lymphocyte (CTL). The CTL’s CD8 co-receptor docks specifically to the conserved α3 domain of the MHC I molecule, stabilizing the interaction while the TCR examines the displayed peptide.
In a healthy cell, the MHC I displays self-peptides, which signals the CTL that the cell is normal and should not be attacked. Furthermore, the presence of self-peptide-loaded MHC I molecules serves as an inhibitory signal to Natural Killer (NK) cells, preventing them from targeting and killing healthy host cells. This mechanism helps to prevent autoimmunity and constitutes the process of “missing self” recognition by NK cells.
However, if the cell is infected by a virus or has become cancerous, the MHC I molecule will predominantly display foreign or abnormal peptides (viral antigens or mutated tumor antigens). Upon recognition of this non-self or abnormal antigen by the CTL’s TCR, the CD8+ T lymphocyte is activated. It then triggers the infected or abnormal cell to undergo programmed cell death (apoptosis), effectively eliminating the internal threat before it can spread, thus establishing the CTL as the main effector cell of the cellular immune response.
The extreme polymorphism of MHC genes—with a large number of alleles for each locus (HLA-A, -B, and -C) in the human population—ensures that a wide variety of peptides can be presented across individuals. This high variability, combined with the polygenic nature of the system (multiple class I genes expressed), makes it difficult for pathogens to evade immune detection entirely. Conversely, this genetic diversity is the main reason why MHC molecules are the major antigens responsible for tissue allograft rejection in organ transplantation, as the recipient’s T cells recognize the donor’s MHC molecules as foreign, leading to an alloresponse and graft destruction. Furthermore, dysregulation or loss of MHC Class I expression is a key immune evasion mechanism utilized by many cancer cells, highlighting its critical role in tumor surveillance.